** Shares of Inari Medical NARI.O rise ~21% premarket to $78.50 premarket
** Larger rival Stryker Corp SYK.N late on Monday agreed to buy NARI in an all-cash deal worth $4.9 billion
** The deal for NARI, which makes devices that treat patients with venous diseases, bolsters Stryker's efforts to expand its offerings to treat venous thromboembolism, a condition where a blood clot forms in a vein, and other vascular diseases
** As part of the deal, which was first reported by Reuters, Stryker will pay $80 per share for Inari
** Up to last close, NARI stock has gained ~2% over the past 12 months
(Reporting by Mariam Sunny in Bengaluru)
((Mariam.ESunny@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.